Companies / Israel
Teva Signals Pause In Acquisitions Quest
May 2006 | Company Finance AlertTeva has also received final approval for Azilect (rasagiline), its proprietary drug for Parkinson's disease, from the US FDA. European and Israeli regulators approved the drug in 2005, and large-scale clinical trials are also under way. Meanwhile, Teva will continue developing the drug with Japanese strategic partner Eisai, which has not yet decided whether to co-promote the drug in the US with the Israeli firm.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
